According to Reuters, Halozyme, in a statement, said "it is our preference to sign a license agreement with any company using our intellectual property to deliver drugs", but it did not comment on potential litigation.
The injected version of Keytruda is still in clinical testing and expected to be launched by early 2026.
Merck has partnered with South Korea-based biopharmaceutical company Alteogen to use a variant of the hyaluronidase family of enzymes, which allows large volume of subcutaneous, or under the skin, administration of drugs through the injected version.
Alteogen's rival Halozyme also utilizes hyaluronidase enzymes to develop injectable versions of various drugs, which include treatments from Roche, Johnson & Johnson, and Pfizer , among others.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.